In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative
the ONA take:
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative to cyclophosphamide plus total body irradiation conditioning regimen for patients with refractory acute myeloid leukemia, according to a new study published online ahead of print in the The Lancet Haematology.
For the study, researchers analyzed data from 514 patients with refractory acute myeloid leukemia in active phase who had received intravenous busulfan plus cyclophosphamide and 338 patients who had received cyclophosphamide plus total body irradiation. All patients then received allogenic hematopoietic stem-cell transplantation from an HLA-identical sibling or an unrelated donor.
Results showed that 2-year overall survival and 2-year leukemia-free survival did not differ between the 2 groups. Researchers found that the main reasons for non-relapse mortality were graft-versus-host disease and infection.
The findings suggest that intravenous busulfan plus cyclophosphamide may be especially preferable for transplant centers that do not have access to radiation facilities.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|